Acrotech Biopharma Launched ADQUEY Ointment

The company introduced a new non-steroidal topical treatment for patients with atopic dermatitis.

Updated on Sept. 30, 2026 in Healthcare

Isometric editorial illustration of a clinical centrifuge and a small glass vial, representing the pharmaceutical industry. — Acrotech Biopharma launched its ADQUEY ointment in the U.S. this week, targeting patients aged two and older with mild-to-moderate atopic dermatitis. AI Illustration. Upload story photo >

Live Poll

Do you believe new pharmaceutical product launches generally improve healthcare access for patients in the U.S.?

Acrotech Biopharma has launched ADQUEY, a 1% difamilast ointment, in the United States. The topical treatment is approved for patients aged 2 years and older with mild-to-moderate atopic dermatitis.

Why it matters

This launch represents a strategic move by Acrotech Biopharma to diversify its portfolio of innovative medicines. By entering the dermatology space, the company aims to establish a long-term presence in a competitive specialty medical sector.

The U.S. dermatology market reached a value of $1.3 billion for the 12 months ended July 2026. The new ADQUEY ointment features a 1% concentration of the active ingredient difamilast.

The players

Acrotech Biopharma

This pharmaceutical company focuses on developing and distributing innovative medicines across several therapeutic areas.

Otsuka Pharmaceutical

This Japanese healthcare company is known for its research into medical treatments and the discovery of the compound difamilast.

Aurobindo Pharma

This global pharmaceutical firm manufactures and markets generic and specialty products across numerous international markets.

The details

Acrotech Biopharma established a dedicated dermatology business unit to support the rollout, incorporating new marketing, sales, and field-based engagement capabilities. The product utilizes difamilast, a compound originally discovered by Otsuka Pharmaceutical and subsequently licensed to Acrotech.

The U.S. dermatology market valuation reflects the 12 months ending in July 2026.
Aurobindo Pharma officially announced the product launch on September 30, 2026.

Market Landscape

This move marks Acrotech Biopharma's expansion into specialty dermatology, a sector currently valued at $1.3 billion. By deploying a dedicated business unit, the company is positioning itself to capture market share against established players in the topical treatment landscape.

Patients aged 2 and older with mild-to-moderate atopic dermatitis may now have access to a non-steroidal treatment option through their healthcare providers. Users should consult with their dermatologists to determine if this new formulation is appropriate for their specific skin condition.

The takeaway

The introduction of new topical inhibitors provides alternative management strategies for chronic dermatological conditions. Patients are encouraged to track treatment outcomes and side effects in coordination with their physicians to optimize long-term skin health.